Home › Trial NCT00810017
Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer
- Trial IDNCT00810017
- StatusTerminated
- PhasePhase 2
- Study typeInterventional
- SponsorMedstar Health Research Institute
- Enrollment2
- Start date2009-02
- ConditionsHER-2 Positive Metastatic Breast Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.